Get a Quote

CAS NO.: 1108743-60-7
Chemical Formula: C31H34F2N6O2
Molecular Weight: 560.6000
DMF&GMP status: Please contact us for more details.
Entrectinib is an orally bioavailable inhibitor of the tyrosine kinases tropomyosin receptor kinases (Trk) A, B and C, C-ros oncogene 1 (ROS1) and anaplastic lymphoma kinase (ALK), with potential antineoplastic activity. Upon administration, entrectinib binds to and inhibits TrkA, TrkB, TrkC, ROS1 and ALK. Inhibition of these kinases may result in a disruption of TrkA-, TrkB-, TrkC-, ROS1-, and ALK-mediated signaling. This leads to an induction of apoptosis and an inhibition of tumor cell proliferation in tumor cells that express these kinases. TrkA, TrkB, TrkC, ROS1 and ALK are overexpressed in a variety of cancer cell types.

Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor. It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positive solid tumors. Entrectinib's approved use is meant as a last line of therapy due to its accelerated approval based on early trial data. This therapy offers benefit over similar ALK inhibitors such as [alectinib], [ceritinib], and [lorlatinib] due to a wider range of targets.

**The products protected by patents in this product catalog are used for laboratory analysis, research and development, and cannot be sold to any country or region with patent protection and for commercial purpose. If the resulting patent infringement risks and responsibilities will be borne by the buyer.
Active Ingredient Dosage Form; Route Strength Proprietary Name Applicant
Patent Data
Patent No. Patent Expiration Drug Substance Claim Drug Product Claim Patent Use Code
867389307/08/2028U-2617 U-2618
925508707/08/2028U-2617 U-2618
964930605/22/2033U-2617 U-2618
1023196502/17/2035U-2617 U-2618
Exclusive Data
Exclusivity Code Exclusivity Expiration
NCE 08/15/2024
ODE-265 08/15/2026
ODE-313 08/15/2026